Immunomodulatory role of histamine H4 receptor in breast cancer by Sterle, Helena Andrea et al.
ARTICLE
Cellular and Molecular Biology
Immunomodulatory role of histamine H4 receptor in
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Helena A. Sterle1, Melisa B. Nicoud2,3, Noelia A. Massari4, Mónica A. Táquez Delgado2, María V. Herrero Ducloux5,
Graciela A. Cremaschi1,3 and Vanina A. Medina2,3
BACKGROUND: Although the role of histamine H4 receptor (H4R) in immune cells is being extensively investigated, its
immunomodulatory function in cancer is completely unknown. This study aimed to investigate the role of H4R in antitumour
immunity in a model of triple-negative breast cancer.
METHODS: We evaluated growth parameters, histological characteristics and the composition of tumour, splenic and tumour
draining lymph node (TDLN) immune subsets, in a syngeneic model, developed orthotopically with 4T1 cells in H4R knockout
(H4R-KO) and wild-type mice.
RESULTS: Mice lacking H4R show reduced tumour size and weight, decreased number of lung metastases and percentage of CD4+
tumour-infiltrating T cells, while exhibiting increased infiltration of NK cells and CD19+ lymphocytes. Likewise, TDLN of H4R-KO mice
show decreased CD4+ T cells and T regulatory cells (CD4+CD25+FoxP3+), and increased percentages of NK cells. Finally, H4R-deficient
mice show decreased Tregs in spleens and non-draining lymph nodes, and a negative correlation between tumour weight and the
percentages of CD4+, CD19+ and NK splenic cells, suggesting that H4R also regulates antitumour immunity at a systemic level.
CONCLUSIONS: This is the first report that demonstrates the participation of H4R in antitumour immunity, suggesting that H4R
could be a target for cancer treatment.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0173-z
INTRODUCTION
Cancer is a major public health issue, representing one of the main
causes of death in the world. Breast cancer is the neoplasm with
the highest incidence among women both in developed countries
and in developing ones.1 During carcinogenesis, the transformed
cells interact with their microenvironment comprising stromal and
immune cells.2
A large body of data revealed the importance of the leukocyte
infiltrate in controlling the clinical progression of various types of
epithelial cancers.3 Cells of immune system are key constituents of
the tumour microenvironment and may promote or inhibit the
development and progression of cancer.4 One of the common
features of most tumour processes is the inflammation that can
contribute to proliferation and survival of malignant cells, promote
angiogenesis and metastasis, altering the responses to hormones
and chemotherapeutic agents.2 On the other hand, the immune
system through tumour immune surveillance, is also responsible
for the removal of nascent tumour cells, preventing tumour
progression and formation of micrometastases.2,5 There are also
immunosuppressive mediators in the tumour microenvironment
that regulate the activity and efficiency of cells with antitumour
capacity, thus controlling the elimination of tumour cells. In this
regard, immunotherapy has emerged as a useful therapeutic
approach for the treatment of many cancers as it stimulates the
immune system to detect and eradicate tumour cells.
Breast cancer was traditionally considered poorly immunogenic
and therefore, immunotherapeutic approaches were not considered
appropriate for its treatment. However, recent studies have shown
that the presence of tumour-infiltrating lymphocytes (TILs) is a
prognostic marker for higher responses to neoadjuvant chemother-
apy and better survival, particularly in triple-negative breast cancer
(TNBC).6 Breast carcinomas are frequently infiltrated by inflamma-
tory cells, mainly macrophages and T lymphocytes, whose
significance has not yet been fully elucidated.7 Several studies
agree, however, that the number of infiltrating CD8+ cells correlates
with better patient survival and response to chemotherapeutic
treatments.8 B cells have also been associated with a favourable
prognosis in breast cancer, although its mechanism of action in
cancer is still under debate.9 In contrast, CD4+ T lymphocytes, which
include regulatory T cells (Treg) and tumour associated macro-
phages, are associated with poorer clinical outcomes. Thus, the
analysis of the tumour infiltrating leukocytes and the study of
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different agents with the ability to modulate the immune response
are currently under consideration, mainly for the treatment of triple
negative breast cancer, that is not only unresponsive to targeted
therapies but also less responsive to conventional therapeutics.6,10
There is an increasing evidence that supports the immunomo-
dulatory roles of histamine under different cytokine environ-
ments11 and it was also described as an important modulator of
haematopoiesis.12 Histamine is a biogenic amine and is one of the
most general biological mediators of mammals, presenting
numerous physiological and pathophysiological functions, which
it exerts through the activation of four different receptor subtypes
H1, H2, H3 and H4 receptors (H1R, H2R, H3R and H4R), which
belong to the family of seven transmembrane domain G-protein-
coupled receptors.12,13 Histamine treatment stimulates the
maturation of dendritic cells from monocytes and promotes the
intratumoural accumulation of these cells, reducing the growth of
murine lymphoma developed with EL-4 cells.14 However, in a
histidine decarboxylase knockout model, endogenous histamine
contributed to the growth of a breast tumour by suppressing the
antitumour immunity.15 Therefore, different histamine metabo-
lism, distinct tumour microenvironment and the histamine
receptor that is involved, may determine the outcome.
H4R is the last discovered member of the histamine receptor
family and is mainly expressed in cells of the immune system, such
as mast cells, eosinophils, monocytes, dendritic cells, T lympho-
cytes and Natural Killer (NK) cells. In peripheral tissues such as the
spleen, thymus and bone marrow its levels of expression are
altered in response to inflammatory stimuli.16 Several lines of
evidence indicate that the H4R plays a key role in both pulmonary
and intestinal inflammatory diseases (asthma, colitis), pruritus,
allergies and other immunological disorders, which has led to the
therapeutic development of novel H4R ligands. This is supported
by results obtained in different experimental models of inflamma-
tion including hepatic ischaemia-reperfusion, colitis, atopic derma-
titis, in which H4R antagonists (JNJ7777120, JNJ10191584,
thioperamide) produce anti-inflammatory effects with reduced
neutrophil recruitment and release of cytokines, improving the
outcome of the pathology.17,18 In some of these models
H4R antagonists produce the same phenotype observed in H4R
knockout mice. Recent clinical trials show that selective H4R
antagonists reduce pruritus in patients with atopic dermatitis
and improve allergic rhinitis, validating preclinical results.17,18
Although the role of H4R in immune cells during inflammatory
disorders is being extensively investigated, its immunomodulatory
function in cancer is completely unknown. This study aimed to
investigate the role of H4R in antitumour immunity in a model of
TNBC. We evaluated growth parameters, histological character-
istics of tumours and the composition of tumour, splenic
and tumour draining lymph node (TDLN) immune subsets in a
syngeneic model of TNBC developed orthotopically with 4T1 cells
in H4R knockout (H4R-KO) and wild-type (WT) mice.
Results show an interplay between H4R expressing immune
cells in tumour microenvironment and cancer cells, which has
implications in breast cancer progression.
MATERIALS AND METHODS
Cell culture
The tumour cell line 4T1 (ATCC CRL-2539) was cultured and was
maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% (v/v) FBS, 0.3 g/l glutamine, 100 µg/ml
streptomycin, and 100 U/ml penicillin (all from Gibco BRL, Grand
Island, NY, USA). Cells were maintained at 37 °C in a humidified
atmosphere containing 5% CO2.
H4R expression
H4R expression in 4T1 cells was determined by RT-PCR and
immunostaining. The retrotranscription reaction and RT-PCR were
performed as previously described.19 Negative controls were
performed with water instead of cDNA and cDNA of H4R-KO mice
spleen. H4R primers and PCR conditions were as followed: H4R-F:
GGC CAA GTG GAT CTC CTG TA, H4R-R: GCT CTG AAA GCA ACC
TAA CTG TG, 500 bp; 3 min 94 °C, 35 cycles of 30 s 94 °C, 30 s 62 °C,
30 s 72 °C. β-actin was used as load control. PCR products were
subjected to gel electrophoresis and visualised using BioDoc-It
Imaging System (USA).
Immunostaining was done as reported.19 Briefly, cells grown on
coverslips were fixed and then incubated overnight in a
humidified chamber at 4 °C with primary goat anti-H4R (1:100,
catalogue number SC-33967, Santa Cruz, USA). After washing, cells
were incubated with FITC-conjugated anti-goat (1:400), and nuclei
were counterstained with Dapi (Sigma Chemical Co., USA) at room
temperature. Coverslips were mounted with FluorSaveTM Reagent
(Calbiochem, USA) and fluorescence was evaluated by using a
Axiovert 200 microscope (Carl Zeiss, Germany).
Animal models
Female histamine H4 receptor knockout (H4R-KO) were generated
as previously described20 and were provided by Janssen Research
& Development, LLC La Jolla, CA, USA and back crossed to BALB/c
background. These animals and the corresponding female wild-
type (WT) mice (BALB/c) were bred and kept in ventilated cages at
our animal health care facility at 22–24 °C and 50–60% humidity
on a 12 h light/dark cycle with food and water available ad libitum.
Animals with an age of 6–8 weeks and an average weight of
20–25 g were used. All animal protocols were supervised and
managed by qualified trained personnel and were in accordance
with recommendations from the National Institute of Health Guide
for the Care and Use of Laboratory Animals (NIH Publications No.
8023) and the Guidelines for the welfare and use of animals in
cancer research. All procedures involving animals were reviewed
and approved by the Institutional Committee for the Care and Use
of Laboratory Animals, BIOMED.
Breast cancer model
To generate solid tumours, 6 to 8-week-old mice were inoculated
orthotopically in the abdominal mammary gland with 1 × 105
syngeneic 4T1 cells in serum-free PBS, as described.21,22 Tumour
length and width were measured every 2 days using callipers, and
tumour volume was calculated as V= π/ 6 × length × width.2,23
After 21 or 28 days, mice were sacrificed, and tissues were
removed and weighted. When indicated, WT mice were daily
treated with subcutaneous injections of JNJ28610244 (JNJ28,
5 mg/kg b.w.), (Janssen Research & Development, San Diego, USA)
for the last 14 days.
Preparation of single-cell suspensions from lymph nodes, spleens
and tumours
After removal, lymphoid organs were disrupted through a 1-mm
metal mesh. Tumours were minced and digested with 2 mg/ml
collagenase type I (Gibco) in serum-free DMEM for 30min at 37 °C.
After centrifugation, the red blood cells from the resulting cell
suspensions were lysed using a buffer containing 150mM NH4Cl,
10 mM K2CO3 and 0.1 mM EDTA and then filtered through a
40-µm cell strainer (BD Biosciences, San José, CA, USA) and
resuspended in PBS.22,23
Flow cytometry for immunophenotyping
Single-cell suspensions obtained from tumours, tumour draining
(TDLN) and non-draining lymph nodes and spleens were stained
with antibodies against various cell surface markers using
standard staining methods, as previously described.22,23 The
following panel of commercially available and fluorochrome
conjugated anti-mouse monoclonal antibodies were used in the
study: FITC-anti-mouse CD3 (BDB-561798), FITC-anti-mouse CD4
(BDB-557307), PE-anti-mouse CD4 (BDB-557307), PE-anti-mouse
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CD8 (BDB-553032), PE-anti-mouse CD19 (BDB-557399), FITC-anti-
mouse Gr1 (BDB-553126), PE-anti-mouse CD11b (BDB-557397),
FITC-anti-mouse CD49 (BDB-561066), FITC-anti-mouse CD44 (BDB-
561859) and APC-anti-mouse CD25 (BDB-558643), all purchased
from BD Biosciences (BDB; San José, CA, USA). Samples were run
on a BD Accury C6 flow cytometer (BDB) and data were analysed
using the BD Accury C6 software (BDB).
Intracellular staining
Single cell suspensions, prepared as described above, were used
for intracellular staining. After surface staining, cells were fixed
with Mouse Fixation Buffer (BD, 51-9006124) and permeabilised
with Mouse Foxp3 Permeabilization Buffer (BDB, 51-9006125),
following manufacturers’ instructions. Cells were then incubated
with the FITC-anti-mouse-FoxP3 antibody (BDB-560408) for
40min. After washing with PBS, cells were analysed by flow
cytometry as described above.
Cytokine determination
Tumours, TDLN and spleens were obtained from mice 28 days
post-tumour inoculation (p.i.). Lymphoid organs were disrupted
through a 1-mm metal mesh and seeded at a final concentration
of 1 × 107 cells/ml in complete RPMI medium. Tumours were cut
in small pieces and equal quantities of tissue were incubated in
complete RPMI medium. After 24 h, the conditioned medium was
obtained. Mice interferon (IFN)-γ (BDB-558473), tumour necrosis
factor (TNF)-α (BDB-558480) and IL-10 (BDB-558300) CBA Flex
Sets (BD Biosciences) were used to analyse specific cytokines in a
BD Accury C6 flow cytometer, following the manufacturers’
instructions. Results were analysed with FCAP Array Software
v3.0 (BDB).
Histochemistry and immunostaining
Tumours and tissues were excised, fixed in 4% (v/v) formaldehyde
in PBS (formalin), paraffin embedded and sliced into 3–4-μm-thick
sections to evaluate the histological characteristics on
haematoxylin–eosin (H&E) stained specimens (Biopur diagnostic,
Buenos Aires, Argentina) as previously described.19
Cell proliferation was assessed by histochemical determination
of PCNA (1:100, clone PC10, Dako Cytomation, Denmark)
expression and by mitotic index (MI), as the number of cells with
visible chromosomes in ×400 magnification fields. Intratumoural
vascularity was evaluated by counting vessels at ×200 magnifica-
tion in 10 random fields. The fragmented DNA was detected using
ApoptagTM plus peroxidase in situ apoptosis Detection Kit
(Millipore, MA, USA) according to the manufacturer’s instructions.
These procedures were described in detail previously.19
Metastatic spread analysis was performed over cuts of excised
organs after staining with H&E. Visualisation was performed with
an optical microscope (Axiolab Carl Zeiss, Germany) and photo-
graphs were taken at ×200 or ×630 magnification with Canon
Power Shot G5 camera (Japan). The immunostaining assessment
was blinded performed by consensus agreement of two observers.
Statistical analysis
Representative results are presented as means ± standard error
of the mean (SEM). Statistical evaluations were made by unpaired
t-test or analysis of variance (ANOVA) that was followed by
Newman–Keuls Multiple Comparison Test. Pearson’s r correlation
coefficient and two-tailed significances were determined when
appropriate. All statistical analyses were performed with GraphPad
Prism version 6.00™ (CA, USA).
RESULTS
H4R-KO mice exhibit reduced tumour growth and metastasis
In agreement with previous studies in human breast cancer cell
lines,24,25 the expression of H4R in 4T1 cells was demonstrated by
RT-PCR and immunostaining (Fig. 1a, b). To investigate the
effect of the H4R-expressing cells in tumour microenvironment
on breast cancer development and progression, H4R-KO and
WT mice were injected orthotopically with 4T1 cells. Both sets of
mice developed tumours, although H4R-KO mice displayed
significantly reduced endpoint tumour size and weight compared
to WT mice (Fig. 2a, b). Histopathological analysis revealed
that H4R-KO mice exhibited areas of tubular differentiation
and reduced nuclear pleomorphism together with decreased
mitotic index and PCNA proliferation marker expression, whereas
WT mice exhibited higher undifferentiation (Fig. 2c, e, f).
Consistent with these results, tumours developed in H4R-KO
mice showed increased apoptosis and decreased vascularisation
along with a reduced number and size of lung micrometastasis
compared to tumours of WT animals (Fig. 2d, g, h, j). In addition,
a positive correlation between tumour weight and the number
of lung metastases was observed in both WT and H4R-KO
mice (Fig. 2i).
Considering the pivotal role of immunity in tumour micro-
environment and that H4R is primarily expressed on immune cells,
the inflammatory infiltrate was next investigated. Tumour-
infiltrating lymphocytes (TILs) were evaluated by FACS. Although
not significant, a higher percentage of TILs was observed in
tumours of H4R-KO mice, whereas no correlation was observed
between TILs and tumour weight (Fig. 3a, b). The analysis of the
distribution of the tumour-infiltrating immune cell subsets was
performed 21 and 28 days post-tumour inoculation and it showed
decreased CD3+ tumour-infiltrating lymphocytes in H4R-KO mice.
However, no changes in the CD8+ T cell subset were detected, but
a decreased percentage of CD4+ T cells in this group lead to a
reduced CD4+/CD8+ ratio. This was accompanied by increased
percentages of NK cells from day 21 in tumours of H4R-KO
compared to WT mice. Also increased CD19+ lymphocytes were
detected in these tumours that became evident only at day 28
(Fig. 3a, c).
CD44 is a marker of T cell activation and its high expression is
one of the most reliable markers for both CD4+ and CD8+
memory T cells in mice.26 No significant differences were
observed in the percentage of CD4+CD44+ (Fig. 3d) or
CD8+CD44+ T lymphocytes (data not shown) in both groups
of animals. Interestingly, further correlation analysis demonstrated
a positive association of CD8+ lymphocytes with tumour
weight, exclusively in H4R-KO mice (Supplementary Table 1).
The analysis of cytokine production in the conditioned medium
of tumours showed no differences in the levels of IFNγ, but a non-
significant increase in TNFα levels in tumours of H4R-KO
mice (Fig. 3e).




Fig. 1 H4R expression was evaluated in 4T1 cells by RT-PCR (a) and
immunostaining (b). a Lanes: MW, DNA ladder molecular size
marker; C- water replace cDNA, 4T1: cDNA of 4T1 cells, KO: spleen
cells of H4R-KO mice were used as negative control. β-actin (521 bp)
was used as load control. b Immunofluorescence (green) of H4R
in 4T1 cells. Nuclei were counter-stained with Dapi (blue). Scale
bar= 20 µm
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Fig. 2 Tumour growth parameters of 4T1 tumour-bearing WT and H4R-KO mice. Comparison of (a) tumour weight and (b) tumour volume at
the end of the experimental period (28 days). Inset: representative pictures of tumours. c, j Representative H&E images of paraffin-embedded
(c) tumours and (j) lungs specimens. c Representative pictures of PCNA-positive immunostaining of tumours (×630 and ×200 original
magnification, Scale bar= 20 µm). d Number of vessels: number of intratumoural vessels at ×200 magnification in 10 random fields (hot
spots). e Mitotic index, number of cells with visible chromosomes at ×400 magnification in 5 random fields. f Percentage of PCNA-positive
cells per field and (g) number of TUNEL-positive cells per field at ×400 magnification in 10 random fields. h Number of microscopic metastatic
foci covering lungs. Error bars represent the means ± SEM of three independent experiments (T-Test, *P < 0.05, **P < 0.01 vs. WT). i Pearson’s
correlation between the number of lung metastases and the tumour weight (correlation coefficient, r: 0.6851, **P= 0.0098 in WT mice.
r: 0.5976, *P= 0.0402 in KO mice)
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Fig. 3 Distribution of immune cell subsets in tumours of 4T1 cells developed in WT and H4R-KO mice. a %TILs: Tumour-infiltrating
lymphocytes percentage. Inset: dot plot: SSC-A vs. FSC-A. b Pearson correlation of TILs vs. tumour weight (P>0.05). c, d Tumour cell
suspensions were obtained 21 or 28 days p.i. of 4T1 cells and were labelled with specific antibodies: CD4-FITC: T helper lymphocytes marker,
CD8-PE: T cytotoxic lymphocytes marker, CD19-PE: B lymphocytes marker, CD49-PE and CD3-FITC: NK markers, CD3-FITC: T lymphocytes
marker, CD44-FITC: activated T lymphocyte marker. Ratio CD4+/CD8+. Error bars represent the means ± SEM of three independent
experiments (T-test, *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT). e Cytokine concentration in tumour-conditioned medium. Error bars represent
the means ± SEM of two independent experiments
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H4R is involved in the regional and systemic antitumour immunity
We next evaluated the role of the H4R in the regional and
systemic immune response by analysing, in WT and H4R-KO
mice, the distribution of immune cells in tumour-draining lymph
nodes (TDLN) and non-draining lymph nodes (LN), respectively.
No significant differences were observed in the percentage of
T (CD3+), B (CD19+) or NK (CD3-CD49+) cells in LN in both groups
(Fig. 4a–f). However, TDLN of WT and H4R-KO mice showed
significant differences in the percentage of these immune cell
subsets. At day 21 p.i., TDLN of H4R-KO mice showed a decreased
percentage of CD3+ lymphocytes. A reduction of CD4+ cells
and increased percentage of NK cells compared to WT mice
became evident at day 28 p.i. of 4T1 cells, while no differences
in the proportion of CD8+ T or CD19+ B lymphocytes were
observed (Fig. 4a–f). However, the percentage of CD4+ activated
T lymphocytes was increased in TDLN of H4R-KO mice, as it
could be determined through CD44 staining in these cells
(Fig. 4g). H4R-KO mice also showed a reduced percentage of
CD4+CD25+FoxP3+ Treg cells in both TDLN and LN when
compared with WT mice (Fig. 4g).
Interestingly, a reduced percentage of CD4+ T lymphocytes and
increased CD19+ B lymphocytes and NK cells were observed in
TDLN compared to non-draining nodes in both WT and H4R-KO
mice (Fig. 4a–f).
As it was observed in tumours, a positive correlation between
the percentage of CD8+ T lymphocytes in TDLN and tumour
weight was detected. On the other hand, a negative association
between the percentage of NK and CD19+ lymphocytes in TDLN
and tumour weight was observed exclusively in H4R-KO mice
(Supplementary Table 2). Additionally, increased levels of TNFα
were measured in conditioned medium of TDLN from H4R-KO
mice, compared to WT, while IFNγ levels were under detection
limits (Fig. 4h).
Spleen regulates innate and adaptive immune responses,
being an essential organ in the systemic antitumour immunity.27
Therefore, the spleens from tumour-bearing animals were further
examined. In line with previous literature,28 a significant increase
in spleen size and weight was observed in 4T1 tumour bearing
animals (Table 1) compared to spleens of mice without tumours
(WT: 0.09 ± 0.01 g, KO: 0.10 ± 0.01 g). Splenomegaly develops
in response and is directly correlated to tumour growth.28 In
agreement with this statement, spleens of tumour-bearing H4R-
KO mice demonstrated a reduced weight in comparison with
the ones of WT mice (Table 1). Similar histologic characteristics,
including red and white pulp areas, were observed in spleens
derived from tumour-bearing H4R-KO and WT mice. Red pulp
areas revealed prominent megakaryocytes and granulocytes
(data not shown).
Furthermore, the distribution of splenic immune cell subsets
was determined in the spleens of 4T1 tumour-bearing WT and
H4R-KO mice. In spite of the negative correlations between
the tumour weight and the percentages of CD3+ T, CD4+ T and
CD19+ B lymphocytes and NK cells in spleen that were found only
in H4R-KO mice at day 28 p.i. (Supplementary Table 3), no
differences were found in the percentages of CD4+ T or CD8+ T,
CD19+ B, NK cells in spleens of tumour bearing H4R-KO mice
compared to WT mice (Table 1). However, splenic Tregs were
decreased in H4R-KO mice (Table 1). Both TNFα and IFNγ levels in
conditioned medium of spleens were found undetectable
(data not shown).
H4R stimulation enhances immunosuppression in 4T1 breast
tumours
To further investigate the immunosuppressive role of H4R, WT
mice were treated with the H4R agonist JNJ28. Even though
the treatment had no effect on the distribution of total CD4+
lymphocytes in TDLN, the percentage of CD4+CD25+FoxP3+ Treg
cells was increased in treated mice (Fig. 5a). Moreover, increased
levels of interleukin (IL)-10 were detected in tumours of treated
mice (Fig. 5b), that were accompanied by decreased levels of IFNγ
(Fig. 5b).
DISCUSSION
During carcinogenesis, the interaction between cancer cells and
immune system remodels the tumour microenvironment to
impair the host immune response, which is recognised as one
of the hallmarks in cancer.2 The identification of the molecular
pathways involved in the dysregulation of tumour immunity is of
outmost importance for the improvement of cancer therapy.
The H4R is the latest characterised histamine receptor and it is
mainly expressed on cells of the haematopoietic lineage.29,30 In
this regard, H4R modulates important immune functions in both
innate and adaptive immune responses.31–33 Reports on the H4R
in mast cells, NK, eosinophils, T cells, monocytes and dendritic
cells demonstrated numerous immune modulating physiological
functions of this receptor, including chemotaxis and pro-
inflammatory cytokine and chemokine release.20,30,34–38
Fig. 4 Distribution of immune cell subsets in tumour draining (TDLN) and non-draining lymph nodes (LN) of 4T1-tumour bearing Balb/c mice.
Cell suspensions from lymph nodes obtained from 21- or 28-day-tumour bearing mice were labelled with specific antibodies: a CD4-FITC:
T helper lymphocytes marker, b CD8-PE: T cytotoxic lymphocytes marker, c CD3-FITC: T lymphocytes marker, d ratio CD4+/CD8+, e CD19-PE:
B lymphocytes marker, f CD49-PE and CD3-FITC: NK markers, g CD44-FITC: activated T lymphocyte marker; CD4-FITC, CD25-APC, FoxP3-PE:
Treg markers. Error bars represent the means ± SEM of three independent experiments (ANOVA and Newman–Keuls Multiple Comparison
Test. *P < 0.05 vs. WT; T-test, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. LN). h TNFα concentration in TDLN-conditioned medium. Error bars represent
the means ± SEM of two independent experiments (T-test, *P < 0.05)
Table 1. Distribution of splenic immune cell subsets and spleen
weight of 4T1 tumour-bearing WT and H4R-KO mice
WT KO
% CD3+ 13.5±1.3 14.3±1.0 P>0.05
% CD4+ 8.8±0.7 9.1±0.4 P>0.05
% CD8+ 6.4±0.6 6.5±0.3 P>0.05
% CD3-CD49+ 2.8±0.4 3.0±0.1 P>0.05
% CD19+ 24.6±2.2 26.5±1.6 P>0.05
% CD4+/CD8+ 1.5±0.3 1.6±0.3 P>0.05























Splenic cell suspensions were obtained from 28-day tumour-bearing mice
and were labelled with specific antibodies: CD3-FITC: T lymphocytes
marker, CD4-FITC: T helper lymphocytes marker, CD8-PE: cytotoxic
T lymphocytes marker, CD49-PE and CD3-FITC: NK markers, CD19-PE:
B lymphocytes marker, CD44-FITC: activated T lymphocyte marker,
CD4-FITC, CD25-APC, FoxP3-PE: Treg markers. Error bars represent the
means ± SEM of three independent experiments (T-Test)
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Accordingly, the receptor is implicated in the pathology of various
immune system-associated diseases such as autoimmune dis-
orders, bronchial asthma and pruritus,39 which highlights the
therapeutic potential of H4R ligands in inflammatory and
autoimmune disorders,40,41 and some of them have reached
clinical scenarios for the treatment of atopic dermatitis and
pruritus.18
The expression of H4R and histamine-induced modulation of
proliferation in different types of tumours has been previously
reported.12,42,43 Functional expression of H4R has been demon-
strated in human breast cancer tissues and cell lines, exhibiting a
key role in histamine-mediated biological processes associated
with cancer progression. In vivo treatments with histamine or H4R
agonists diminished the growth rate of human TNBC developed
in immune-deficient nude mice with MDA-MB-231 cells.43,44
In agreement with these results, the H4R agonist
4-methylhistamine significantly decreased the tumour volume
and increased the survival of mice bearing xenograft non-small
cell lung cancer tumours.45 In addition, H4R agonists significantly
increased the median survival and decreased the tumour volume
in vivo in two human melanoma experimental models.19,42
However, all these studies were performed in immunodeficient
hosts, where the role of the immune system in the response to
anti-cancer treatments and tumour progression could not be
evaluated and therefore, they may not mimic the real clinical
situation.
Although it is well established that the immune tumour
microenvironment is a major participant in cancer cell prolifera-
tion, invasion and metastasis; the role of H4R in the antitumour
immunity is completely unknown. In the present study we aimed
to investigate the immunomodulatory role of H4R in breast
cancer, evaluating growth parameters and the composition of
tumour, splenic and TDLN immune subsets in a syngeneic model
of TNBC developed orthotopically with 4T1 cells in H4R-KO and
WT mice. The 4T1 tumour model in immunocompetent mice
resembles human TNBC as it leads to metastasis formation in
various organs, including the lung, brain and bone and is widely
used for the preclinical determination of antitumour therapies to
evaluate the role of the immune system in the tumour
development and progression.22,46
Results show that H4R selectively affects the distribution of
different immune cell populations in the tumour microenviron-
ment, modulating the local and systemic immune responses.
Hosts with H4R deficiency exhibited reduced tumour growth that
was correlated with a reduced number of lung metastasis. This
fact could determine the disease outcome, as metastasis is the
primary cause of death in breast cancer patients. Metastasis
formation is regulated not only by the tumour cells but also by
unique molecular signals from the tumour microenvironment47
and the immune response induced by the primary tumour, which
plays important roles in all steps of the metastatic cascade.48
The reduced tumour growth was associated with a decreased
angiogenesis and different immune cell infiltration. It is well
documented that tumour growth is strongly related to neovascu-
larisation. In this work, a reduced number of intratumoural vessels
was observed in H4R-KO mice, which could contribute to the
decreased size and proliferation of these tumours. In line with this
study, laser choroidal neovascularisation volume was reduced in
H4R-KO mice.47 On the other side, other reports demonstrated
that H4R may negatively regulate angiogenesis, since H4R
agonists attenuate angiogenesis in Leydig tumours48 and
melanoma.44 The study of the exact role of H4R in tumour
angiogenesis is still unexplored and deserves further investigation.
On the other hand, the outcome of the antitumour immunity is
determined by the type of the developed immune response and
TILs, including NK and cytotoxic CD8+ T cells, are known to protect
against tumour development and progression.49 In this regard,
























































































Fig. 5 Treatment of tumour-bearing WT mice with the H4R agonist JNJ28610244, JNJ28 (5 mg/kg b.w.). a Cell suspensions from TDLN
obtained from 28-day tumour-bearing mice were labelled with specific antibodies: CD4-FITC, CD25-APC, FoxP3-PE. b IL-10 and IFNγ cytokine
concentration in tumour-conditioned medium. Error bars represent the means ± SEM of two independent experiments (T-Test, *P < 0.05)
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factor in different solid tumours, including breast cancer.50 In
addition, TDLN are used as prognostic markers in breast cancer.
They have a dual role in tumour development, as they can induce
antitumour immune responses but they can also act as routes for
malignant cells towards distant organ metastasis in response to
different factors released by tumours.51
Our results show a decreased ratio of CD4+/CD8+ lymphocytes
in tumours and TDLN of H4R-KO mice that could contribute for the
slower growth rate of these tumours. In fact, CD8+ T-cell infiltrates
are generally associated with better prognosis while CD4+ T cells,
which include T-regulatory cells, have been associated with worse
outcomes.8 Immunohistochemical analysis of tissue microarrays
derived from 179 treatment-naive breast tumours revealed that
high levels of CD4+ T cells correlated with reduced overall survival
(OS), while high levels of CD8+ T cells combined with low levels of
CD4+ T cells correlated with increased OS.52
It is known that T lymphocytes express H4R and that its
expression is higher in resting than in activated T cells.53 However,
very little is known about the role of this receptor in T cells.
Gantner et al.11 described that H4R, together with H2R, are
involved in the control of IL-16 release from human CD8+ T cells.11
IL-16 is believed to play an important role in the recruitment of
CD4+ T cells mainly in inflammatory diseases, but it is also
involved in breast cancer and other tumours.54–56 In a murine
model of allergic inflammation, H4R-KO mice showed reduced
lung infiltrating T cells accompanied with decreased Th2
responses.57 Moreover, in a chronic model of atopic dermatitis,
H4R-KO mice showed amelioration of the skin lesions and
displayed a reduced number of splenocytes and lymph node
cells with a decreased number of CD4+ T cells.58 In this model,
the H4R also modulated the cytokine secretion of CD4+ T cells
and splenocytes and altered the cellular profile in the lymph
nodes. Additionally, the treatment with the H4R agonist
4-methylhistamine in a murine model of chronic stress has been
shown to increase the number of CD4+ cells and the production
of Th1 cytokines in whole blood.59
A more exhaustive analysis on CD4+ cells showed no
differences in the percentage of activated CD4+ infiltrating
lymphocytes and no Tregs could be detected in tumours. On
the other hand, TDLN of H4R-KO exhibited reduced Tregs
compared to WT mice. Although TDLN of H4R-KO mice showed
a higher percentage of activated cells within CD4+ subset, total
activated CD4+ cells were similar in both groups. It is important to
highlight the increased presence of Tregs in TDLNs compared to
non-draining LN in both groups. This has been well established in
both animal models and cancer patients, where accumulation of
Tregs in TDLNs and not in tumour is correlated with disease
progression.51 In addition, treatment with a specific H4R agonist,
JNJ2828610244, significantly increased the percentage of Tregs in
TDLN of WT mice. IL-10 is a well-known immunosuppressive
cytokine, which is secreted by tumour cells and Tregs among
other immune cells and has an important role in tumour
immunosurveillance.60 On the other hand, IFNγ is a pleiotropic
molecule with antitumour effects, which is produced primarily by
cytotoxic CD8+ T lymphocytes and NK cells.61 H4R stimulation
enhanced IL-10 while decreased IFNγ levels in tumour conditioned
medium of WT mice, suggesting an immunosuppressive role of
H4R in the context of 4T1 breast cancer model.
In line with these results, it has been previously demonstrated
that H4R regulates Tregs activity. In a murine model of allergic
asthma, the treatment with the H4R agonist 4-methylhistamine
resulted in accumulation of FoxP3+ T cells with potent suppressive
activity for proliferation.62 Likewise, H4R was described to play a
critical role in determining the frequency of Tregs in secondary
lymphoid tissues in a model of allergic encephalomyelitis, as it
regulates Treg chemotaxis and suppressor activity. Moreover, the
lack of H4R leads to an impairment of an anti-inflammatory
response due to fewer Tregs in the central nervous system during
the acute phase of the disease.63 Tregs have been described to
limit NK cell numbers by direct granzyme B and perforin-
dependent killing in TDLN.64 NK cells perform several important
functions, including the regulation of the adaptive immune
response by secreting cytokines like IFNγ and producing the lysis
and destruction of tumour cells.35 NK cells constitutively express a
lytic machinery capable of killing target cells independently of
antigen presentation.65 The expression of the H4R in NK cells was
determined at the protein level35 and the stimulation of these
cells with the H4R agonist ST1006 showed increased production of
CCL366 and induced NK cell chemotaxis in vitro, which was
inhibited with the H4R antagonist JNJ7777120.67 However, our
results show an increased percentage of NK cells in tumours and
TDLN of H4R-KO mice when compared with WT mice, indicating
an increased chemotaxis to the tumour site of these cells in mice
lacking the H4R. This effect should be an early event in tumour
development, considering that the increase in NK tumour
infiltration is evident at 28 but also 21 days post 4T1 cells’
injection. These animals also showed increased levels of TNFα in
TDLN and, although no significant, in tumours, which could be
related to NK cell activity, even though no differences were
observed in the production of IFNγ.
In agreement with present results, NK cells were shown to play
important roles in tumour immune surveillance, in the prevention of
tumour progression and against metastatic dissemination in
numerous murine models.68,69 Most human tumours display low
levels of NK cells and their increased infiltration is associated with an
improved prognosis and reduction of tumour recurrence.68 Surpris-
ingly, the increase in tumour-infiltrating NK cells and the decrease
in CD4+ T cells in tumours of H4R-KO mice was followed by an
increment of CD19+ lymphocytes, that was observed at day 28 p.i.
of 4T1 cells, even if they show very low expression of H4R.55
Infiltrating CD19+ B lymphocytes have been much less evaluated as
prognostic or predictive factors in breast cancer. Their presence
within breast lesions is about 20% of total TILs, and has been
associated with more favourable prognosis due to the ability of
these lymphocytes to differentiate into granzyme B-secreting cells.6
We hypothesise that the differences observed in the percen-
tages of tumour-infiltrating B cells could be due to the interaction
of NK cells and B cells through both indirect and direct pathways.
NK cells lead to B cell activation and induce class switching of
immunoglobulins produced through CD40–CD40 ligand interac-
tion and through the production of various cytokines.70 Addition-
ally, B cell secreted antibodies may lead to antibody-dependent
cell-mediated cytotoxicity by NK cells.70 Interestingly and in line
with this, negative associations between the percentages of NK
cells and CD19+ lymphocytes and tumour weight were observed
in TDLN exclusively in H4R-KO mice.
The spleen is involved in the systemic regulation of immunity. It
has no afferent lymph vessels and collects its leukocytes directly
from blood. Besides circulating immune cells that continuously
migrate into and out of the resting spleen, different diseases can
recruit additional cells to the organ.27 Spleen weight of H4R-KO
mice was lower than the one of the WT mice, together with a
reduced tumour size of the former animals. Although no
differences were observed between groups regarding immune
cell subsets distribution, the tumour weight negatively correlates
with splenic CD4+, CD19+ and NK cell percentages only in H4R-KO
mice. Therefore, it is possible that tumour growth and dissemina-
tion may be also regulated by H4R at a systemic level. Noteworthy,
there is a decrease in the percentage of Tregs in spleens and non-
draining LN of H4R-KO mice, which could favour the systemic
immune responses, thus reducing tumour progression.
Present findings demonstrate that histamine through H4R plays
important roles at a variety of stages during tumour development
and in multiple cell types including cancer cells and immune cells.
H4R not only may participate in the modulation of cancer cell
proliferation but also in the response of tumour immunity further
Immunomodulatory role of histamine H4 receptor in breast cancer
H. A. Sterle et al.
9
supporting the complexity of cancer. Current studies are focused
on evaluating the immunomodulatory role of H4R in other cancer
models.
As far as we know, this is the first report showing the
participation of H4R in the anti-tumour immunity, highlighting
the therapeutic potential of H4R ligands as adjuvants to cancer
therapy, modulating immune response. Further studies are
needed to determine the exact role of H4R in cancer biology,
considering the triggered effects in H4R expressing cells in the
tumour and in the immune tumour microenvironment, as a whole,
in order to improve the benefit of cancer patients.
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